ES2556243T3 - Agentes terapéuticos que contienen bacteriófagos - Google Patents

Agentes terapéuticos que contienen bacteriófagos Download PDF

Info

Publication number
ES2556243T3
ES2556243T3 ES04743566.4T ES04743566T ES2556243T3 ES 2556243 T3 ES2556243 T3 ES 2556243T3 ES 04743566 T ES04743566 T ES 04743566T ES 2556243 T3 ES2556243 T3 ES 2556243T3
Authority
ES
Spain
Prior art keywords
ncimb
deposited
aeruginosa
panel
therapeutic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04743566.4T
Other languages
English (en)
Inventor
James Soothill
Catherine Hawkins
David Harper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocontrol Ltd
Original Assignee
Biocontrol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0317240A external-priority patent/GB0317240D0/en
Priority claimed from GB0410855A external-priority patent/GB0410855D0/en
Application filed by Biocontrol Ltd filed Critical Biocontrol Ltd
Application granted granted Critical
Publication of ES2556243T3 publication Critical patent/ES2556243T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Panel de bacteriófagos adecuado para tratar una infección bacteriana que comprende o consiste en Pseudomonas aeruginosa, en el que cada miembro de dicho panel tiene una diferente especificidad de cepa para P. aeruginosa, y en el que el panel consiste en dos o más bacteriófagos seleccionados del grupo que consiste en: (i) las cepas de bacteriófagos depositadas NCIMB 41174, NCIMB 41175, NCIMB 41176, NCIMB 41177, NCIMB 41178, NCIMB 41179, NCIMB 41180 y NCIMB 41181 (depositadas en la National Collection of Industrial and Marine Bacteria, Aberdeen, Reino Unido); y (ii) mutantes de las cepas depositadas que conservan la capacidad de dirigirse a P. aeruginosa, en el que dicho mutante tiene una identidad en la secuencia de nucleótidos de al menos el 98% o al menos el 99% a lo largo de la totalidad de su genoma en comparación con el genoma de la pertinente cepa depositada.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21

Claims (1)

  1. imagen1
ES04743566.4T 2003-07-23 2004-07-23 Agentes terapéuticos que contienen bacteriófagos Expired - Lifetime ES2556243T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0317240A GB0317240D0 (en) 2003-07-23 2003-07-23 Therapeutic agents
GB0317240 2003-07-23
GB0410855 2004-05-14
GB0410855A GB0410855D0 (en) 2004-05-14 2004-05-14 Therapeutic agents
PCT/GB2004/003237 WO2005009451A1 (en) 2003-07-23 2004-07-23 Bacteriophage-containing therapeutic agents

Publications (1)

Publication Number Publication Date
ES2556243T3 true ES2556243T3 (es) 2016-01-14

Family

ID=34105984

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12195158.6T Expired - Lifetime ES2527994T3 (es) 2003-07-23 2004-07-23 Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa
ES04743566.4T Expired - Lifetime ES2556243T3 (es) 2003-07-23 2004-07-23 Agentes terapéuticos que contienen bacteriófagos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES12195158.6T Expired - Lifetime ES2527994T3 (es) 2003-07-23 2004-07-23 Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa

Country Status (7)

Country Link
US (5) US7807149B2 (es)
EP (2) EP2570130B1 (es)
JP (2) JP5731727B2 (es)
AU (1) AU2004258731B2 (es)
CA (1) CA2533352C (es)
ES (2) ES2527994T3 (es)
WO (1) WO2005009451A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5731727B2 (ja) * 2003-07-23 2015-06-10 バイオコントロール リミテッド バクテリオファージ含有治療薬
AU2006219739A1 (en) * 2005-03-04 2006-09-08 Blaze Venture Technologies Limited Method and device for bacterial sampling
CN100363489C (zh) * 2005-06-16 2008-01-23 华中科技大学同济医学院附属同济医院 一株耐亚胺培南绿脓杆菌噬菌体及其用于治疗耐亚胺培南绿脓杆菌感染的用途
JP5127708B2 (ja) 2005-07-12 2013-01-23 マイクレオス べスローテン フェンノートシャップ バクテリオファージ及びその使用
US8178087B2 (en) 2006-04-04 2012-05-15 Centre National de la Recherche Scientifique —CNRS Process of production of bacteriophage compositions and methods in phage therapy field
GB0704553D0 (en) * 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments
WO2009076668A2 (en) * 2007-12-13 2009-06-18 Alpharma, Inc. Bacteriophage preparations and method of use thereof
US9320795B2 (en) * 2007-12-13 2016-04-26 Zoctis Server LLC Bacteriophage preparations and methods of use thereof
KR20100093626A (ko) * 2009-02-17 2010-08-26 서강대학교산학협력단 슈도모나스 애루지노사에 대한 파아지 치료
WO2010141135A2 (en) 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
TW201130980A (en) * 2010-03-02 2011-09-16 Univ Ishou A new lytic phage specific to Klebsiella pneumoniae
CA2837731C (en) 2011-06-28 2018-05-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Controlled covalent attachment of bioactive bacteriophage for regulating biofilm development
US8669226B2 (en) 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
US12083158B2 (en) 2011-10-07 2024-09-10 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
CA2871986C (en) * 2012-05-04 2020-11-03 Biocontrol Limited Therapeutic bacteriophage compositions
DE102013106455A1 (de) 2013-06-20 2014-12-24 Airbus Defence and Space GmbH Verfahren zur Dekontamination von bakteriologischen Verunreinigungen
PL405911A1 (pl) 2013-11-04 2015-05-11 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Białko o aktywności hydrolitycznej wobec polisacharydowych otoczek bakteryjnych, polinukleotyd kodujący to białko, biologicznie czynny wektor, kompozycja zawierająca białko i jego zastosowanie
WO2016168560A1 (en) 2015-04-16 2016-10-20 Kennesaw State University Research And Service Foundation, Inc. Escherichia coli o157:h7 bacteriophage φ241
US10517908B2 (en) 2015-08-13 2019-12-31 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions
PT3440200T (pt) * 2016-04-08 2021-04-30 Phico Therapeutics Ltd Bacteriófago modificado
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2017189518A1 (en) * 2016-04-25 2017-11-02 Yale University Bacteriophage compositions and uses thereof
WO2018146437A1 (en) 2017-02-13 2018-08-16 Biocontrol Limited Therapeutic bacteriophage compositions
CN109837251B (zh) * 2017-11-27 2022-01-28 菲吉乐科(南京)生物科技有限公司 一种噬菌体保护剂及其制备方法和应用
AU2019205241B2 (en) 2018-01-02 2025-10-16 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infections
US11654166B2 (en) 2018-01-02 2023-05-23 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions for treating Staphylococcus infection
CN108300723B (zh) * 2018-01-17 2022-04-08 天津科技大学 应用于筛选生物被膜抑制剂的报告基因系统
EP3749342B1 (en) 2018-02-07 2024-07-10 Armata Pharmaceuticals, Inc. Bacteriophage for treatment and prevention of bacteria-associated cancers
WO2019231848A1 (en) 2018-05-30 2019-12-05 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
US20210369797A1 (en) 2018-10-04 2021-12-02 Western Sydney Local Health District Bacteriophage treatment and reduction in inflammatory response
CN114844614B (zh) * 2019-08-02 2024-12-27 华为技术有限公司 一种提升终端设备测量能力的方法、芯片以及终端设备
CA3187281A1 (en) * 2020-06-15 2021-12-23 Laboratory Corporation Of America Holdings Methods for the diagnosis and treatment of biofilm-related infections
US12016892B2 (en) * 2021-04-09 2024-06-25 University of Pittsburgh the Commonwealth System of Higher Education Bacteriophages for treatment of tuberculosis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678750A (en) 1984-10-18 1987-07-07 Microlife Technics, Inc. Method and compositions for use in the treatment of fireblight
US4828999A (en) * 1986-07-21 1989-05-09 Jackson Le Roy E Bacteriophage prevention and control of harmful plant bacteria
SU1472500A1 (ru) 1987-07-28 1989-04-15 Тбилисский Научно-Исследовательский Институт Вакцин И Сывороток Штамм бактериофага РSеUDомоNаS aeRUGINoSa, используемый дл идентификации и индикации микробов РSеUDомоNаS aeRUGINoSa
US5032574A (en) 1988-05-26 1991-07-16 Invitron Corporation Novel antimicrobial peptide
US5242902A (en) 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
JPH07507213A (ja) 1992-05-22 1995-08-10 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 消化器デフェンシン，そのｃＤＮＡ配列及び製造方法並びにその使用
WO1994019006A1 (fr) 1993-02-24 1994-09-01 Gunze Limited Remede contre la fibrose kystique
US5459235A (en) 1993-03-19 1995-10-17 The Regents Of The University Of California Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils
US5550109A (en) 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia
EP0895534A1 (en) 1996-04-15 1999-02-10 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
WO1998047521A1 (en) 1997-04-24 1998-10-29 Idaho Research Foundation, Inc. Phages, methods for growing and detecting them and their use
US20020037260A1 (en) 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
DE69838473T2 (de) 1997-12-25 2008-01-17 Nihon Kohden Corp. Gerät zur Übertragung von biologischen Signalen
WO1999037799A1 (en) 1998-01-21 1999-07-29 The Secretary Of State For Defence Antibiotic sensitivity testing
US20040208853A1 (en) * 2000-01-11 2004-10-21 Intralytix, Inc. Method and device for sanitation using bacteriophages
EP1250053A2 (en) 2000-01-11 2002-10-23 Intralytix Inc. Method for produce sanitation using bacteriophages
US20020001590A1 (en) * 2000-04-20 2002-01-03 Mount Sinai Hospital Antibacterial therapy for multi-drug resistant bacteria
US6485902B2 (en) * 2000-06-06 2002-11-26 Thomas E. Waddell Use of bacteriophages for control of escherichia coli O157
CA2417188A1 (en) * 2000-07-25 2002-01-31 Carl R. Merril Bacteriophage having multiple host range
US6461608B1 (en) * 2000-11-22 2002-10-08 Nymox Pharmaceutical Corporation Bacteriophage composition useful in treating food products to prevent bacterial contamination
RU2186574C1 (ru) 2001-01-24 2002-08-10 Яфаев Рауэль Хасанянович Препарат поливалентного бактериофага против синегнойной палочки, штаммы бактериофага bacteriophagum pseudomonas aeruginosa спбгма им. и.и. мечникова №05, №03, №06 и №07, используемые при приготовлении поливалентного препарата против синегнойной палочки
DE60218473T2 (de) * 2001-07-18 2007-11-08 Instytut Immunologii I Terapii Doswiadczalnej - Pan Verfahren zur herstellung polyvalenter bakteriophagenpräparationen zur behandlung bakterieller infektionen
GB0300597D0 (en) * 2003-01-10 2003-02-12 Microbiological Res Authority Phage biofilms
US6804620B1 (en) 2003-03-21 2004-10-12 Advantest Corporation Calibration method for system performance validation of automatic test equipment
JP5731727B2 (ja) 2003-07-23 2015-06-10 バイオコントロール リミテッド バクテリオファージ含有治療薬
US20050051420A1 (en) 2003-09-05 2005-03-10 Sharper Image Corporation Electro-kinetic air transporter and conditioner devices with insulated driver electrodes
GB0704553D0 (en) 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments

Also Published As

Publication number Publication date
JP2013049700A (ja) 2013-03-14
WO2005009451A9 (en) 2006-05-18
AU2004258731B2 (en) 2010-02-25
US7807149B2 (en) 2010-10-05
US20120114611A1 (en) 2012-05-10
EP2570130A1 (en) 2013-03-20
JP5856556B2 (ja) 2016-02-10
JP2006528166A (ja) 2006-12-14
US8388946B2 (en) 2013-03-05
US20070190033A1 (en) 2007-08-16
US9687514B2 (en) 2017-06-27
CA2533352C (en) 2016-01-19
CA2533352A1 (en) 2005-02-03
EP1663265A1 (en) 2006-06-07
US20180055895A1 (en) 2018-03-01
EP1663265B1 (en) 2015-09-23
WO2005009451A1 (en) 2005-02-03
JP5731727B2 (ja) 2015-06-10
US20110020290A1 (en) 2011-01-27
EP2570130B1 (en) 2014-11-26
AU2004258731A1 (en) 2005-02-03
ES2527994T3 (es) 2015-02-03
US8105579B2 (en) 2012-01-31
US20130209408A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
ES2556243T3 (es) Agentes terapéuticos que contienen bacteriófagos
Henriksen et al. P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage–ciprofloxacin combination: —monitoring the phage–P. aeruginosa biofilms interactions
Avila-Novoa et al. Biofilm formation by Staphylococcus aureus isolated from food contact surfaces in the dairy industry of Jalisco, Mexico
Nair et al. Antibiofilm activity and synergistic inhibition of Staphylococcus aureus biofilms by bactericidal protein P128 in combination with antibiotics
Fu et al. Inhibition of Pseudomonas aeruginosa biofilm formation by traditional Chinese medicinal herb Herba patriniae
Jamal et al. Isolation and characterization of a bacteriophage and its utilization against multi-drug resistant Pseudomonas aeruginosa-2995
Falkinham III et al. Proliferation of antibiotic-producing bacteria and concomitant antibiotic production as the basis for the antibiotic activity of Jordan's red soils
Chankhamhaengdecha et al. Endophytic actinomycetes: a novel source of potential acyl homoserine lactone degrading enzymes
JP2006528166A5 (es)
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
CO5601048A2 (es) Evento de algodon mon 88913 y composiciones y metodos para su deteccion
WO2001098317A3 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
EP4537828A3 (en) Phospholipid compounds and uses thereof
Pumbwe et al. Evidence for multiple-antibiotic resistance in Campylobacter jejuni not mediated by CmeB or CmeF
Nowicki et al. Phenethyl isothiocyanate inhibits shiga toxin production in enterohemorrhagic Escherichia coli by stringent response induction
Hajialilo et al. Molecular characterization of bacterial, viral and fungal endosymbionts of Acanthamoeba isolates in keratitis patients of Iran
Moussa et al. A novel multiplex PCR for molecular characterization of methicillin resistant Staphylococcus aureus recovered from Jeddah, Kingdom of Saudi Arabia
Kock et al. Orientia tsutsugamushi is highly susceptible to the RNA polymerase switch region inhibitor Corallopyronin A in vitro and in vivo
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
WO2005046454A3 (en) Methods of using gelsolin to treat or prevent bacterial sepsis
Rahmat Ullah et al. Effectiveness of a lytic phage SRG1 against vancomycin‐resistant Enterococcus faecalis in compost and soil
Grami et al. Siphoviridae bacteriophage treatment to reduce abundance and antibiotic resistance of Pseudomonas aeruginosa in wastewater
Mauro et al. The microcosm mediates the persistence of shiga toxin-producing Escherichia coli in freshwater ecosystems
EA200400197A1 (ru) Способы получения поливалентных бактериофагов для лечения бактериальных инфекций
Li et al. Effect of the three Enterococcus faecalis strains on apoptosis in MC 3T3 cells